NanoViricides Files FDA Orphan Drug Bid for NV-387
Shelton, Connecticut — February 10, 2026: NanoViricides, Inc., a clinical-stage antiviral nanomedicine company, announced the filing of an Orphan...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Shelton, Connecticut — February 10, 2026: NanoViricides, Inc., a clinical-stage antiviral nanomedicine company, announced the filing of an Orphan...
Nanobiotix S.A. (Euronext: NANO, NASDAQ: NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches for cancer and other serious...
Vancouver, Canada, Oct. 28, 2025 — Augurex Life Sciences announced FDA Breakthrough Device Designation for its SPINEstat® blood test,...
Dallas, TX – October 24, 2025: OncoNano Medicine, a clinical-stage biotechnology company, announced it will present new data at...
